Navigation Links
Human Genome Sciences Announces Full Presentation of Quality-of-Life Results From Phase 2b Trial of Albuferon(R) for Hepatitis C
Date:11/5/2007

persist in the blood for at least six months, a person is diagnosed with chronic hepatitis C. Hepatitis C virus can cause serious liver disease, leading to cirrhosis, primary liver cancer and even death.

About Human Genome Sciences

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, anthrax disease, cancer and other immune-mediated diseases. The Company's primary focus is rapid progress toward the commercialization of its two key lead drugs, Albuferon for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. Phase 3 clinical trials of both drugs are ongoing.

ABthrax(TM) (raxibacumab) is in late-stage development for the treatment of anthrax disease, and the Company is on track to begin the delivery in 2008 of 20,000 doses of ABthrax to the Strategic National Stockpile under a contract entered into with the U.S. Government in June 2006. Other HGS drugs in clinical development include two TRAIL receptor antibodies for the treatment of cancers.

For more information about HGS, please visit the Company's web site at http://www.hgsi.com. To view the AASLD oral presentation reporting results of the Phase 2b clinical trial of Albuferon in combination with ribavirin in treatment-naive patients (Zeuzem, et al), click here. To view the AASLD poster presentation reporting quality of life results from the Phase 2b clinical trial of Albuferon (Pianko, et al), click here. To view the AASLD oral presentation reporting results of the Phase 2 trial of Albuferon in non- responders (Nelson, et al), click here. To view the AASLD poster presentation reporting results of a prospective comparison of commercial fibrosis serum marker panels (Patel, et al), click here. For more information about Albuferon, please visit

SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)...  TNI BioTech, Inc. (OTCQB: TNIB) ("TNIB" or ... development, marketing and distribution of opioid-related immunotherapies, announced ... with the Securities and Exchange Commission in connection ... be held on Thursday, September 4, 2014, at ... for determining those shareholders eligible to receive notice ...
(Date:7/28/2014)... , July 28, 2014 Concord Medical Services ... CCM ), a leading specialty hospital management solution ... and diagnostic imaging centers in China ... Board of Directors declared a special cash dividend of ... Share ("ADS")) on the Company,s outstanding ordinary shares. The ...
(Date:7/28/2014)... 2014 OmPrompt gab ... £ investiert hat, um die weltweite Nachfrage ... und Logistikbranche zu erfüllen. Albion wird Teil ... http://photos.prnewswire.com/prnh/20140728/697982 ) In ... beschleunigtes Wachstum mit Investitionen in seine Plattform, ...
Breaking Medicine Technology:TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 3Concord Medical Declares Special Dividend 2OmPrompt erhält Finanzierung für Marktexpansion von Kundenautomatisierungsmanagement 2
(Date:7/28/2014)... (PRWEB) July 28, 2014 With California ... it is welcome news that a fire blanket ... current protection is under development by SunSeeker Enterprises, Inc. ... to protect spacecraft from the extreme heat of re-entry ... both firefighters and homes. , “Our firefighters routinely lay ...
(Date:7/28/2014)... bumping" transmits significantly fewer bacteria than either handshaking ... of hand-to-hand contact between patients and clinicians, according ... of the American Journal of Infection Control ... Professionals in Infection Control and Epidemiology (APIC). , ... Environmental, and Rural Sciences at Aberystwyth University in ...
(Date:7/28/2014)... North America Carotenoids & Antioxidants Market report defines and segments ... and forecast of revenue. This market is estimated to grow ... 2018, at a CAGR of 7.1% from 2013 to 2018. ... & Antioxidants Market report to get an idea of the ... segmentation in the market, and is supported by various tables ...
(Date:7/28/2014)... the July, 2014, issue of the Journal ... Medicine researchers, sheds new light on the risks ... in the treatment of localized, early-stage esophageal cancer. ... while more invasive, provided significantly better outcomes with ... than endoscopic resection, which had a 76 percent ...
(Date:7/28/2014)... New York (PRWEB) July 28, 2014 ... edition of “Organic Living” on March 12th, a campaign ... an organic lifestyle. In partnership with industry leader ... over 100 Certified Organic teas, the campaign provides readers ... recent years that continues to propel the industry forward ...
Breaking Medicine News(10 mins):Health News:Revolutionary Fire Blanket Offers Over 200 Percent More Fire Protection to Firefighters and Homes 2Health News:Fist-bumping beats germ-spreading handshake, study reports 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Study helps compare risks of treatments for early esophageal cancer 2Health News:Study helps compare risks of treatments for early esophageal cancer 3Health News:Mediaplanet's "Organic Living" Campaign Raises Awareness About What Nature Invented, With the Help of Partner TEALUX 2
... -- A Wayne State University study published in the January ... that two influential early studies of cellphone use and crash ... cellphones while driving. In this new study, Richard Young, ... Psychiatry and Behavioral Neurosciences in the School of Medicine, examined ...
... HealthDay Reporter , WEDNESDAY, Dec. 14 (HealthDay News) ... may one day also prove useful in combating serious cases ... Journal of Infectious Diseases finds that patients hospitalized with ... a statin, compared with their peers who weren,t taking one ...
... Institute for Operations Research and the Management Sciences (INFORMS) ... Society Frank P. Ramsey Medal to Dr. Don N. ... market leading provider of web-based financial analytics and performance ... health systems to enhance their financial planning, budgeting, and ...
... by some as being a potent stimulant, but the debate ... of expert opinions capture the scope of this ongoing debate ... Caffeine Research , a quarterly peer-reviewed journal from Mary Ann ... www.liebertpub.com/jcr . Led by Journal of Caffeine Research ...
... Lyon has developed an animal model carrying a mutation of the ... can no longer induce the death of the cancer cells. This ... treatment that aims to reactivate the dying of cancer cells. ... in the 11th December 2011 issue of the journal Nature ...
... face a steep learning curve to get used to new ... before new total knee replacement procedures are as safe and ... operations using a new device in a hospital are 48 ... undergoing an operation to fit a prosthesis previously used in ...
Cached Medicine News:Health News:Wayne State study shows early research on cellphone conversations likely overestimated crash risk 2Health News:Could Statins Help Those Hospitalized With Flu? 2Health News:INFORMS presents Ramsey Medal to health care financial analytics executive Don Kleinmuntz 2Health News:A gene that protects against colorectal cancers 2Health News:Patients at risk of knee joint complications when new technology is used 2
The S8 Escape is the economy model of ResMeds S8 series. The S8 Escape is ideal for patients who want the convenience and portability of the S8 models but do not require the added comfort features of...
... REMstar Plus with C-Flex combines ... and the comfort of C-Flex.With ... REMstar Plus with C-Flex offers ... deliver sleep therapy by taking ...
... a display, ramp capabilities and ... has features that make set-up ... meter records the number of ... four hours - giving you ...
REMstar Pro with C-Flex is a combination of the advances from our other products. The difference is the C-Flex waveform which offers a more comfortable way to deliver sleep therapy by taking the work...
Medicine Products: